| Literature DB >> 28619238 |
Anjali Athanerey1, Pradeep Kumar Patra2, Awanish Kumar3.
Abstract
Venous leg ulcers (VLU) are a prevalent and reoccurring type of complicated wound, turning as a considerable public healthcare issue, with critical social and economic concern. There are both medical and surgical therapies to treat venous leg ulcers; however, a cure does not yet exist. Mesenchymal stem cells (MSC) are capable and proved of accelerating wound healing in vivo and their study with human chronic wounds is currently awaited. MSCs are a promising source of adult progenitor cells for cellular therapy and have been demonstrated to differentiate into various mesenchymal cell lineages. They have a crucial and integral role in native wound healing by regulating immune response and inflammation. Improved understanding of the cellular and molecular mechanisms at work in delayed wound healing compels to the development of cellular therapy in VLU. This review focuses on the current treatment option of VLU and further emphasizing the role of MSCs in accelerating the healing process. With further understanding of the mechanism of action of these cells in wound improvement and, the involvement of cytokines can also be revealed that could be used for the therapeutic purpose for VLU healing. Clinical uses of MSCs have been started already, and induced MSCs are surely a promising tool or compelling therapy for VLU.Entities:
Keywords: Growth factors; Mesenchymal stem cells; Therapy; Venous leg ulcer
Mesh:
Year: 2017 PMID: 28619238 DOI: 10.1016/j.jtv.2017.06.001
Source DB: PubMed Journal: J Tissue Viability ISSN: 0965-206X Impact factor: 2.932